Reviewed by Michael Gill, B. Sc.
Image of Centers for Disease Control and Prevention in Atlanta, United States.
Phase-Based Progress Estimates
1
Effectiveness
1
Safety

Influenza A/H5N1 Vaccinefor Flu caused by Influenza

18+
All Sexes
This is a single center, open-label, Phase I/II study in up to 100 adult subjects, aged 18 years and older who are at occupational risk of exposure to live H5N1 viruses. This study is designed to investigate the safety, reactogenicity, and immunogenicity of two 90 µg doses of an investigational inactivated influenza A/H5N1 virus vaccine given approximately 28 days apart. A blood sample will be collected for immunogenicity evaluation prior to each vaccination. Subjects will maintain a memory aid (appendix C4 and C13) to record oral temperature and systemic and local AEs for 7 days after immunization. Subjects will be encouraged to take their temperature around the same time each day. All subjects will receive a safety follow-up telephone call at 1 to 3 days after each vaccination (approximately Day 2) to elicit any AE and concomitant medication information. Subjects will return to the clinic 7 days after each vaccination for assessment of AEs and concomitant medications, a targeted physical examination (if indicated), and review of the memory aid. At approximately Day 28 after the first vaccination, subjects will return to the clinic for evaluation of vital signs, blood sample collection and safety follow-up, confirmation of eligibility criteria and a second vaccination. Safety follow-up will be identical to that performed after the first vaccination. At approximately Day 56 (or about 28 days after the second vaccination), subjects will return to the clinic for immunogenicity blood sample collection, AE and concomitant medication assessment, and targeted physical examination and vital sign assessment (if indicated). At approximately Day 180 (6 months after the first vaccination), subjects will return to the clinic for a final immunogenicity blood sample collection and safety assessment. Blood samples collected prior to each vaccination (Days 0 and 28) and on Days 56 and 180 after the first vaccination will be tested at the CDC Influenza Division Laboratory for the levels of neutralizing and HAI antibodies and CMI responses. The primary outcome measures will be the frequencies and severities of AEs and the GMTS and proportions of subjects who achieve 4-fold rises in serum neutralizing and HAI titers against the influenza A/H5N1 virus on Day 56. Serum HAI and neutralizing antibody responses (including frequencies of 4 fold or greater rise in titer; GMTs; and proportions of subjects achieving protective titers of neutralizing antibody 1 month and 6 months after first dose) will also be assessed. A secondary outcome measure will be CMI responses evaluated 1 month after the receipt of each dose of vaccine and 6 months after the receipt of the first dose of vaccine.
Phase 1 & 2
Waitlist Available
Centers for Disease Control and PreventionCarolyn Bridges, MD
25 Influenza Clinical Trials Near Me
Top Hospitals for Influenza Clinical Trials
Image of Meridian Clinical Research, LLC in Nebraska.
Meridian Clinical Research, LLC
Omaha
4Active Trials
10All Time Trials for Influenza
2004First Influenza Trial
Image of Sundance Clinical Research, LLC in Missouri.
Sundance Clinical Research, LLC
Saint Louis
4Active Trials
6All Time Trials for Influenza
2016First Influenza Trial
Top Cities for Influenza Clinical Trials
Influenza Clinical Trials by Phase of Trial
Phase < 1 Influenza Clinical Trials
3Active Influenza Clinical Trials
3Number of Unique Treatments
0Number of Active Locations
LAIVSingle Influenza VaccineTreatment Group Live Attenuated Flu Vaccine (LAIV)
Influenza Clinical Trials by Age Group
< 18 Influenza Clinical Trials
7Active Influenza Clinical Trials
FluadSing2016 M2SR H3N2RIV4 cohortVaxelis2018-19 quadrivalent inactivated influenza vaccineBaloxavir MarboxilTrivalent Influenza Vaccine
Top Treatments for Influenza Clinical Trials
Treatment Name
Active Influenza Clinical Trials
All Time Trials for Influenza
First Recorded Influenza Trial
Influenza Vaccine
4
12
2008
Baloxavir Marboxil
3
9
2016
Trivalent Influenza Vaccine
3
6
2008
Baloxavir
2
2
2020
High Dose Quadrivalent Inactivated Influenza Vaccine
2
2
2021
Recently Completed Studies with FDA Approved Treatments for Influenza
Treatment
Year
Sponsor
Cam2020 M2SR H3N2 influenza vaccine
2022
FluGen Inc
Quadrivalent High-dose Influenza Vaccine
2021
Janssen Vaccines & Prevention B.V.
aQIV
2021
Seqirus
Flu D-QIV vaccine
2021
GlaxoSmithKline
Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2021-2022 formulation
2021
Sanofi Pasteur, a Sanofi Company
Tezepelumab
2021
AstraZeneca
Influenza RG-A/Texas/71/2017 (H3N2) Challenge
2021
National Institute of Allergy and Infectious Diseases (NIAID)
Quadrivalent Inactivated Influenza High Dose
2021
Sanofi Pasteur, a Sanofi Company
mRNA-1010
2021
ModernaTX, Inc.
Sodium Pyruvate
2021
Cellular Sciences, inc.

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 4th, 2021

Last Reviewed: November 28th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References1 Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, Fukuda K. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003 Jan 8;289(2):179-86. https://pubmed.ncbi.nlm.nih.gov/125172282 De Vlaminck I, Valantine HA, Snyder TM, Strehl C, Cohen G, Luikart H, Neff NF, Okamoto J, Bernstein D, Weisshaar D, Quake SR, Khush KK. Circulating cell-free DNA enables noninvasive diagnosis of heart transplant rejection. Sci Transl Med. 2014 Jun 18;6(241):241ra77. doi: 10.1126/scitranslmed.3007803. https://pubmed.ncbi.nlm.nih.gov/249441923 De Vlaminck I, Martin L, Kertesz M, Patel K, Kowarsky M, Strehl C, Cohen G, Luikart H, Neff NF, Okamoto J, Nicolls MR, Cornfield D, Weill D, Valantine H, Khush KK, Quake SR. Noninvasive monitoring of infection and rejection after lung transplantation. Proc Natl Acad Sci U S A. 2015 Oct 27;112(43):13336-41. doi: 10.1073/pnas.1517494112. Epub 2015 Oct 12. https://pubmed.ncbi.nlm.nih.gov/264600484 Hayden FG, Sugaya N, Hirotsu N, Lee N, de Jong MD, Hurt AC, Ishida T, Sekino H, Yamada K, Portsmouth S, Kawaguchi K, Shishido T, Arai M, Tsuchiya K, Uehara T, Watanabe A; Baloxavir Marboxil Investigators Group. Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents. N Engl J Med. 2018 Sep 6;379(10):913-923. doi: 10.1056/NEJMoa1716197. https://pubmed.ncbi.nlm.nih.gov/301844555 Skowronski DM, Hottes TS, De Serres G, Ward BJ, Janjua NZ, Sabaiduc S, Chan T, Petric M. Influenza Β/Victoria antigen induces strong recall of Β/Yamagata but lower Β/Victoria response in children primed with two doses of Β/Yamagata. Pediatr Infect Dis J. 2011 Oct;30(10):833-9. doi: 10.1097/INF.0b013e31822db4dc. https://pubmed.ncbi.nlm.nih.gov/218572636 Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ, Fukuda K. Influenza-associated hospitalizations in the United States. JAMA. 2004 Sep 15;292(11):1333-40. https://pubmed.ncbi.nlm.nih.gov/153675557 Ledgerwood JE, Zephir K, Hu Z, Wei CJ, Chang L, Enama ME, Hendel CS, Sitar S, Bailer RT, Koup RA, Mascola JR, Nabel GJ, Graham BS; VRC 310 Study Team. Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect. J Infect Dis. 2013 Aug 1;208(3):418-22. doi: 10.1093/infdis/jit180. Epub 2013 Apr 30. https://pubmed.ncbi.nlm.nih.gov/236334078 Phrommintikul A, Kuanprasert S, Wongcharoen W, Kanjanavanit R, Chaiwarith R, Sukonthasarn A. Influenza vaccination reduces cardiovascular events in patients with acute coronary syndrome. Eur Heart J. 2011 Jul;32(14):1730-5. doi: 10.1093/eurheartj/ehr004. Epub 2011 Feb 2. https://pubmed.ncbi.nlm.nih.gov/212890429 Memoli MJ, Czajkowski L, Reed S, Athota R, Bristol T, Proudfoot K, Fargis S, Stein M, Dunfee RL, Shaw PA, Davey RT, Taubenberger JK. Validation of the wild-type influenza A human challenge model H1N1pdMIST: an A(H1N1)pdm09 dose-finding investigational new drug study. Clin Infect Dis. 2015 Mar 1;60(5):693-702. doi: 10.1093/cid/ciu924. Epub 2014 Nov 20. https://pubmed.ncbi.nlm.nih.gov/2541675310 Falsey AR, Treanor JJ, Tornieporth N, Capellan J, Gorse GJ. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis. 2009 Jul 15;200(2):172-80. doi: 10.1086/599790. https://pubmed.ncbi.nlm.nih.gov/19508159